- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Orange, California • Santa Monica, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 150
- States / cities
- Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib, Amivantamab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib, Amivantamab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 701 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 12 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Docetaxel
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Irvine, California • Los Alamitos, California • Orange, California + 3 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 17
- States / cities
- Duarte, California • La Jolla, California • Orange, California + 14 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q
- Interventions
- BLU-451, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
- Interventions
- Amivantamab, Lazertinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Lung Cancer Metastatic, EGFR Gene Mutation
- Interventions
- Osimertinib, Alisertib
- Drug
- Lead sponsor
- Collin Blakely
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
- Conditions
- Advanced or Metastatic Colorectal Cancer
- Interventions
- Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
- Interventions
- Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 46 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Fountain Valley, California • Fairfax, Virginia • Renton, Washington
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Stanford, California + 21 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cetrelimab, Amivantamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Los Alamitos, California + 3 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Amivantamab, Tepotinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Esophagogastric Cancer
- Interventions
- Amivantamab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Irvine, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Osimertinib, Lazertinib, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 20
- States / cities
- Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Irvine, California • Long Beach, California + 13 more
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Biological · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 248
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 211 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib, Amivantamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Cerritos, California • Los Angeles, California + 2 more